Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Your big brain makes you human – count your neurons when you count your blessings - 2Defeating An inability to embrace success in Scholarly world: Individual Victories
- 3Opening Achievement: 8 Methodologies for Compelling Using time productively
- 4Instructions to Pick the Right Toothpaste for Your Dental Requirements
- 5Figure out how to Team up with Your Auto Crash Legal advisor for Best Outcomes
- Ukrainian man arrested in Germany on suspicion of spying for Russia
- Hamas Navy head, engineer of Khan Yunis tunnel network killed in Gaza, IDF confirms
- A Manual for Pick High Evaluated Food Conveyance Administrations In Significant Urban communities For 2024
- The 3 little words TV fans can't stop obsessing over
- The most effective method to Guarantee Simple Availability in Seniors' SUVs
- 5 Instructive Toy Brands for Youngsters
- Verdicts against social media companies carry consequences. But questions linger
- Live long and loiter: Why NASA's ESCAPADE probes will wait a year in space before heading to Mars
- General Atlantic says ‘biggest mistake’ would be pulling back on Gulf deals
